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1. Introduction 
NK cells are a key component of the innate immune system, which can act early in defences 
against virally infected and tumor cells (Robertson and Ritz 1990; Bottino, Moretta, and 
Moretta 2006; Bancroft 1993). They have the capacity to secrete proinflammatory cytokines 
and lyse their targets without prior antigen sensitization (Cooper, Fehniger, and Caligiuri 
2001). They are also involved in regulation of the adaptive immune response through their 
interaction with dendritic cells (DCs)(Sanabria et al. 2008; Smyth et al. 2005). 
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Activation of NK cells is regulated through the integration of signals from a number of 
activating and inhibitory receptors(Lanier 2005). Many of the inhibitory receptors use major 
histocompatibility complex (MHC) class I or class I-like proteins as their ligands(Lanier 
2005). The interaction between inhibitory NK receptors and their ligands during NK cell 
development is important in educating these cells for subsequent function and for avoiding 
reactivity to normal cells expressing self MHC class I (Kim et al. 1969; Anfossi et al. 2006). In 
humans one large family of NK receptors are encoded by the Killer Immunoglobulin-like 
Receptors (KIR) region that maps to chromosome 19q13.4 (Lanier 2005). The most 
polymorphic locus among the KIR region genes is KIR3DL1, which encodes both inhibitory 
KIR3DL1 (3DL1) and activating KIR3DS1 (3DS1) alleles (Norman et al. 2007). 3DL1 alleles 
can be further classified according to their expression levels on the cell surface into high (*h), 
low/intermediate (*l) and null (*004) (not cell surface expressed) alleles (Yawata et al. 2006; 
Norman et al. 2007; Gardiner et al. 2001; Pando et al. 2003). Genotypes homozygous for 
3DL1 can be divided into 2 groups: *h/*y, where *y can be either another *h allele or *004 
with no *l alleles, and *l/*x, where *x can be an *l, *x or *004 allele (Martin et al. 2007). 3DL1 
receptors recognize a subset of MHC class I HLA-B molecules known as Bw4. HLA-Bw4 
differ from the remaining HLA-Bw6 antigens encoded at this locus, which do not interact 
with 3DL1, in the amino acids present between positions 77 and 83 of the HLA heavy chain 
(Wan et al. 1986). Bw4 allotypes with isoleucine at position 80 (Bw4*80I) have been reported 
to be better ligands for many of the 3DL1 alleles (Cella et al. 1994). However, there is 
evidence that Bw4 antigens with threonine at position 80 (Bw4*80T), particularly HLA-
B*2705, interact strongly with certain 3DL1 receptors (Luque et al. 1996). 
Epidemiological studies have reported that several KIR/HLA combinations are associated 
with slower progression to AIDS and suppression of viral load (VL) (Martin et al. 2007). 
Compared to Bw6 homozygotes (hmz) the 3DL1/HLA-B combination having the most potent 
influence on slowing time to AIDS and VL control is 3DL1*h/*y with HLA-B*57 
(*h/*y+B*57)(Martin et al. 2007). Previous work from our group showed that NK cells from 
individuals carrying this genotype combination demonstrated higher functional potential 
than those from carriers of either the NK receptor genotype or HLA-B*57 alone or from Bw6 
hmz (Boulet et al. 2010). In these studies functional potential was defined as the percent 
contribution of NK cells secreting interferon-γ (IFNγ) and tumor necrosis factor-α (TNF-α) 
and expressing CD107a, a marker of degranulation to the total response to stimulation with 
the HLA devoid K562 cell line. Furthermore, NK cells from carriers of *h/*y+B*57 had higher 
functional potential than carriers of 3DL1*h/*y with other Bw4 alleles(Boulet et al. 2010). 
HLA-B*57 is an HLA antigen considered to be protective in the context of HIV 
infection(Kaslow, Dorak, and Tang 2005; Altfeld et al. 2003; Leslie et al. 2004; Carrington, 
Martin, and van Bergen 2008). While the protective effect conferred by HLA-B*57 is 
mediated at least in part through CD8+ T cell recognition of HIV epitopes restricted by this 
antigen, epidemiological studies and our results support the possibility that HLA-B*57’s 
protective effect may also be mediated through its ability to educate NK cells for superior 
functional potential (Martin et al. 2002; Martin et al. 2007; Leslie et al. 2004; Miura et al. 2009; 
Leslie et al. 2005). 
Murine models have shown using single MHC class I transgenic mice that MHC class I 
molecules can differ from each other in the potency of their NK education signals, which 
directly translates into activation potency upon encountering cells lacking that MHC ligand 
(Brodin, Karre, and Hoglund 2009). Since NK cells from *h/*y+B*57 carriers had higher 
functional potential than carriers of 3DL1*h/*y with other Bw4 alleles, HLA-B*57 may be an 
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example in humans of an MHC class I antigen with an NK education potency that is 
superior to that of most other HLA-Bw4 molecules. HLA-B*27 is another allele considered to 
be protective in the context of HIV infection (Kaslow et al. 1996; Carrington and Bontrop 
2002; Goulder, Edwards et al. 1997; Trachtenberg et al. 2003). Like HLA-B*57, its protective 
effect is mediated at least in part through immune pressure exerted by CD8+ T cells 
(Schneidewind et al. 2009; Goulder, Phillips et al. 1997; den Uyl, van der Horst-Bruinsma, 
and van Agtmael 2004; Goulder et al. 2001). In this report we questioned whether HLA-
B*27, like HLA-B*57, could also act as a ligand for 3DL1 NK receptors that was superior to 
other HLA-Bw4 alleles in terms of its ability to educate NK cells for functional potential. 
HLA-B*27 is found at a higher frequency among the approximately 5% of HIV infected 
individuals that we have classified as Slow Progressors (SP) compared with HIV infected 
individuals exhibiting a typical rate of disease progression or uninfected subjects 
(Carrington, Martin, and van Bergen 2008; Kaslow, Dorak, and Tang 2005). SP are defined 
by either exhibiting spontaneous control of viremia or maintaining CD4 counts >400 
cells/mm3 for at least 7 years post-infection (Madec et al. 2005; Deeks and Walker 2007). In 
order to determine whether HLA-B*27, like HLA-B*57, could educate NK cells from 3DL1 
hmz individuals for superior functional potential we compared the functional potential of 
NK cells from 3DL1 hmz+B*27 (3DL1+B*27) carriers with that from 3DL1 hmz who were Bw6 
hmz (3DL1+Bw6) or who expressed at least 1 Bw4 alleles other than B*57 or B*27 
(3DL1+Bw4). NK cells from 3DL1+B*27 carriers had a significantly higher functional 
potential than those from 3DL1+Bw6. When the functional potential of NK cells from 
carriers of the 3DL1 NK receptor /HLA-B ligand pairs *h/*y+B*57, 3DL1+B*27 and 
3DL1+Bw4 were compared we observed decreasing levels in the functional potential where 
NK cells responded to missing self with a h/*y+B*57 > 3DL1+B*27 > 3DL1+Bw4 hierarchy.  
2. Materials and methods 
2.1 Study population 
A total of 51 HIV-infected SP were studied. Forty four were from the Canadian Cohort of 
HIV Infected Slow Progressors and 7 were from a cohort followed at the National Institutes 
of Allergy and Infectious Diseases (NIAID) (Migueles et al. 2008). The term SP was used 
here to define treatment naïve HIV infected subjects who maintained absolute CD4 counts 
above 400 cells/mm3 for more than 7 years or who were followed for at least 1 year with VL 
<3000 copies/ml of plasma. Information on CD4, CD8 T cell counts, VL and duration of 
infection at time of testing, 3DL1 genotype and HLA-B allotype of the study population is 
provided in Table 1. All individuals in the study populations are 3DL1 hmz to eliminate the 
possible confounding effect on NK function of expressing the activating 3DS1 receptor, 
which is an allele at this locus (Martin et al. 2007; Boulet et al. 2008; Yawata et al. 2006). The 
study population is classified into 4 groups: group 1 (n=12) carry the 3DL1+B*27 genotype, 
group 2 (n=13) are 3DL1+Bw4, group 3 (n=14) are 3DL1+Bw6 and group 4 (n=12) are 
*h/*y+B*57. Informed consent was obtained from all study subjects and research conformed 
to the ethical guidelines of the authors’ institutions. 
2.2 MHC and KIR typing 
All subjects were typed for MHC class I alleles by sequence-based typing using kits from 
Atria Genetics (South San Francisco, CA) and Assign software to interpret sequence 
information for allele typing (Conexio Genetics, Perth, Australia) as previously described 
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(Boulet et al. 2010). HLA-Bw6 hmz subjects lacked any HLA-Bw4 alleles at the HLA-A or B 
locus. 3DL1/S1 genotyping was performed using two sets of primers specific for the 3DL1 
and 3DS1 alleles at the 3DL1 locus as previously described (Boulet et al. 2008). Subjects were 
subsequently 3DL1 allotyped by identifying single nucleotide polymorphisms (SNP) 
corresponding to high frequency 3DL1 alleles as previously described (Boulet et al. 2010). In 
our study we categorized 3DL1*005, *006, *007, *053, *054 as *l alleles, 3DL1*001, *002, *008, 
*009, *015, *020 as *h alleles and *004 as a null allele.  
 
Subjects 
ID 
gender1 Age2
Time 
infected2 
Group3 HLA-B1 HLA-B2
KIR 
genotype4
CD45 CD85 VL6 
1001 M 59 2.9 1 B15:01 B27:05 *h/*y 760 900 1.7 
1002 M 59 14.6 1 B15:01 B27:05 *h/*y 788 2498 4.12 
1003 M 61 23.5 1 B27:02 B67:01 *h/*y 670 1050 4.7 
1004 M 49 20.2 1a B27:05 B57:01 *h/*y 830 1700 3.91 
1005 M 37 2.5 1 B27:05 B40:02 *h/*y 1040 1090 1.7 
1006 M 40 3.7 1 B14:02 B27:05 *h/*y 820 570 1.7 
1007 M 71 5.2 1 B27:03 B51:01 *l/*x 590 114 1.7 
1008 F 31 1.2 1a B27:05 B57:01 *l/*x 489 672 1.7 
1009 F 59 13.2 1 B27:03 B49:01 *l/*x 692 627 1.7 
1010 M 38 2.3 1 B15:01 B27:05 *l/*x 396 936 1.7 
1011 M 63 25.0 1 B27:05 B51:01 *h/*y 340 748 1.7 
1012 M 41 6.4 1 B07:02 B27:05 *l/*x 710 970 3.25 
2001 M 35 6.5 2 B15:02 B51:02 *l/*x 500 NA 3.24 
2002 F 39 15.9 2 B49:01 B58:02 *h/*y 400 510 3.54 
2003 M 15 8.0 2 B38:01 B51:01 *h/*y 596 1614 2.08 
2004 M 45 16.2 2 B07:02 B51:01 *h/*y 440 350 3.54 
2005 F 46 14.7 2 B07:02 B38:01 *l/*x 720 720 1.7 
2006 M 47 17.0 2 B39:01 B35:01 *h/*y 546 572 5.21 
2007 M 46 1 2 B53:01 B58:01 *l/*x 870 550 1.7 
2008 M 49 7.3 2 B44:03 B53:01 *l/*x 360 1610 2.8 
2009 F 40 2.8 2 B07:02 B13:01 *h/*y 1487 712 3.76 
2010 F 50 6.9 2 B15:03 B44:02 *h/*y 590 1650 3.73 
2011 F 44 22.2 2 B44:02 B52:02 *h/*y 420 1180 3.15 
2012 F 32 5.1 2 B14:02 B44:03 *l/*x 715 384 1.7 
2013 F 36 6.3 2 B49:01 B53:01 *h/*y 535 793 2.43 
3001 M 34 3.0 3 B07:02 B14:02 *l/*x 680 890 2.85 
3002 M 40 14.4 3 B14:02 B15:01 *h/*y 343 804 1.7 
3003 M 40 4.7 3 B14:02 B14:02 *h/*y 350 730 3.41 
3004 M 40 3.4 3 B07:02 B07:02 *h/*y 985 605 3.3 
3005 M 46 5.6 3 B15:10 B41:01 *l/*x 530 390 1.7 
3006 F 42 4.0 3 B07:05 B35:01 *l/*x 919 1557 1.7 
3007 F 57 3.1 3 B07:02 B42:01 *l/*x 636 663 1.7 
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Subjects 
ID 
gender1 Age2
Time 
infected2 
Group3 HLA-B1 HLA-B2
KIR 
genotype4
CD45 CD85 VL6 
3008 M 53 4.1 3 B07:02 B14:02 *h/*y 447 455 3.3 
3009 M 29 4.2 3 B07:02 B14:02 3DL1 hmz 516 788 2.89 
3010 F 61 14.3 3 B07:02 B18:01 *l/*x 810 1050 1.7 
3011 F 39 6.6 3 B42:01 B45:01 *h/*y 620 408 2.69 
3012 M 39 9.9 3 B14:02 B40:06 *h/*y 720 1820 2.59 
3013 M 46 7.0 3 B07:02 B07:05 *h/*y 970 1210 1.94 
3014 M 62 17.5 3 B14:01 B81:01 *h/*y 650 2110 4.46 
4001 F 39 3.0 4 B57 B7 *h/*y 1443 895 1.7 
4002 F 55 23.8 4 B57 B57 *h/*y 277 385 1.7 
4003 M 58 20.5 4 B57 B15 *h/*y 883 590 1.7 
4004 M 41 11.2 4 B40:01 B57:01 *h/*y 1200 860 1.7 
4005 M 61 11.0 4 B40:02 B57:01 *h/*y 770 990 3.9 
4006 M 45 14.9 4 B07:02 B57:01 *h/*y 650 1460 4.21 
4007 F 39 2.6 4 B35:01 B57:01 *h/*y 530 NA 1.7 
4008 M 24 2.0 4 B07:02 B57:01 *h/*y 680 880 3.1 
4009 M 49 10.0 4 B57 B13 *h/*y 955 881 1.7 
4010 M 58 18.0 4 B57 B44 *h/*y 1329 1243 1.7 
4011 M 46 21.0 4 B57 B81 *h/*y 1362 1055 1.7 
4012 M 36 7.0 4 B57 B52 *h/*y 780 739 1.7 
Table 1. Study population characteristics. 1 M=male/ F=female, 2 in years, 3 1= 3DL1+B*27; 
2=3DL1+Bw4; 3=3DL1+Bw4; 4=*h/*y+B*57. The 2 subjects with the 1a designation carry 
both a B*27 and B*57 allele, 4 the individual classified as 3DL1 hmz has not been allotyped 
for KIR3DL1 alleles, 5 cells/mm3, 6 VL= log10 viral load copies/ml plasma. 
2.3 Cells  
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation (Ficoll-Paque Pharmacia Upsala, Sweden) from whole blood obtained by 
venipuncture into tubes containing EDTA anti-coagulant or by leukaphersis as previously 
described (Boulassel et al. 2003). Cells were cryopreserved in 10% DMSO (Sigma-Aldrich, St. 
Louis, MO) with 90% fetal bovine serum (FBS, Wisent, St. Bruno, Quebec, Canada). 
2.4 NK cell functional potential 
Cryopreserved PBMC were thawed and resuspended at 106 cells/ml in RPMI 1640 (Wisent) 
that contained 10% FBS (Wisent), 2mM L-glutamine and 50 IU penicillin and 50µg/ml 
streptomycin (Wisent). Brefeldin A (at 5µg/ml, Sigma-Aldrich), Monensin (at 6µg/ml, 
Golgi-Stop; BD Biosciences, Mississauga, Ontario, Canada) and anti-CD107a–FITC mAb (BD 
Biosciences) were added to the cells. One million PBMCs were stimulated with media alone 
or HLA devoid K562 cells (American Type Culture Collection Manassas, VA) at a PBMC to 
K562 cell ratio of 5:1 or with 1.25µg/ml phorbol 12-myristate 13-acetate (PMA); 0.25µg/ml 
ionomycin, (Sigma-Aldrich) as a positive control for 6 hours at 37oC in a humidified 5% CO2 
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incubator. All stimulation data shown is from cells that generated a positive result in the 
PMA and ionomycin stimulation condition.  
Cells were stained for viability using the Aqua LIVE/DEAD® fixable dead cell stain kit 
(Invitrogen, Burlington, Ontario, Canada) following manufacturer’s instructions. Cells 
were then stained for cell surface markers with anti-CD56-APC, anti-CD16-Pacific Blue (BD 
Biosciences), anti-CD3-ECD and CD158e-PE (ie: Z27-PE, Beckman Coulter, Mississauga, 
Ontario, Canada) for 30 min. After washing with phosphate buffered saline (PBS) 
containing 1% FBS (Wisent), cells were fixed and permeabilized using the Fix and Perm Kit 
(Invitrogen) and stained for intracellular cytokines using anti-IFN--Alexa 700 and anti-
TNF--PE-Cy7 (BD Biosciences). Cells were washed and fixed with 1% paraformaldehyde 
solution (Fisher Scientific, Ottawa Ontario, Canada) and kept in the dark at 4oC until 
acquisition. 
2.5 Flow cytometry analysis 
Between 400,000 and 500,000 events were acquired per sample using an LSRII flow 
cytometer (BD Biosciences). Analysis for NK cell activation was performed using FlowJo 
software version 9.1 (Tree Star, San Carlos, CA). The functional profiles of stimulated NK 
cells were determined using a gating strategy where NK cells were defined as CD3-CD56+/-
CD16+/-. Boolean gating was used to identify seven NK cell functional profiles, i.e. tri-
functional NK cells (CD107a+ IFN-+ TNF-+), bi-functional NK cells (any combination of 
two of these functions) and mono-functional NK cells (any single one of these functions). All 
results for the frequency of individual functional subsets were background corrected by 
subtracting the frequency of positive NK cells in the unstimulated subset. Corrected results 
were used to generate the percent contribution of each functional subset to the total NK cells 
response to K562. Results reported as subset frequency or percent contribution of a subset to 
the total K562 response showed a high level of correlation with each other (Boulet et al. 
2010).  
2.6 Statistical analysis 
GraphPad Instat 3.05 and GraphPad Prism 5.04 were used for statistical analyses and 
graphical presentations. A Kruskal-Wallis test was used to assess the significance of 
between group differences in age, duration of infection at the time point tested, CD4 counts, 
CD8 counts and VL. Mann-Whitney U tests were used to test the significance of between 
group differences in the percent contribution of an NK cell functional subset to the total NK 
cell response. A Spearman correlation test was used to test the significance of the trend 
towards declining tri-functional potential with 3DL1/HLA-B genotype combinations. A p 
value of <0.05 was considered significant.  
3. Results 
3.1 Study population 
Table 2 provides information on the average and standard deviation for age, duration of 
infection, CD4 count, CD8 count and log10VL at the time point tested for NK functional 
potential for SP classified as 3DL1+B*27, 3DL1+Bw4, 3DL1+Bw6 and *h/*y+B*57 described in 
Table 1. No between-group differences were seen for any of these parameters (Krukal-Wallis 
test). 
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3DL1+B*27 
(n=12) 
3DL1+Bw4 
(n=13) 
3DL1+Bw6 
(n=14) 
*h/*y+B*57 
(n=12) 
Age1 50.7 ± 12.83 40.1 ± 9.5 44.9 ± 10.0 45.9 ± 11.0 
Duration of infection1 10.1 ± 8.9 10.0 ± 6.5 7.2 ± 4.8 12.1 ± 7.6 
CD42 677 ± 198 619 ± 306 655 ± 211 904 ± 363 
CD82 989 ± 606 887 ± 494 963 ± 533 907 ± 292 
Log10 VL 2.53 ± 1.2 2.95 ± 1.0 2.57 ± 0.86 2.21 ± 0.95 
Table 2. Summary of study population characteristics. I In years, 2 Cells/mm3, 3 Means ± 
standard deviation. 
3.2 NK cells from 3DL1+B*27 carriers have a higher functional potential than those 
from 3DL1+Bw6 
To investigate whether NK cells from HIV-infected SPs carrying the 3DL1+B*27 genotype 
for an NK receptor/HLA-B ligand pair differ in their NK cell functional potential compared 
to Bw6 hmz with no ligand for 3DL1 receptors, we measured the frequency of NK cells 
expressing CD107a and secreting IFN- and TNF- from K562-stimulated NK cells using 
eight colour multi-parametric flow cytometry. In this analysis CD107a expressing NK cells 
were the sum of the mono-, bi- and tri-functional functional subsets expressing CD107a. 
This was also the case for IFN-γ and TNF-α secreting NK cells. As shown in Figure 1A the 
median (range) frequency of NK cells from 3DL1+B*27 versus 3DL1+Bw6 carriers expressing 
CD107a was 6.92% (3.01%, 17.15%) versus 4.27% (0.74%, 13.32%), secreting IFN-γ was 8.91% 
(4.25%, 21.52%) versus 5.17% (0.55%, 25.92%) and secreting TNF-α was 0.92% (0.11%, 3.67%) 
versus 0.23% (0.01%, 3.06) (p<0.05 for all comparisons; Mann-Whitney test). Therefore, the 
frequency of NK cells with any of these functions was significantly greater when NK cells 
were from 3DL1+B*27 individuals than from 3DL1+Bw6. 
Since we simultaneously measured these three functions following K562 stimulation we 
were able to assess the frequency of seven possible NK cell functional profiles and their 
percent contribution to the total K562 response. Figure 1B shows the percent contribution of 
each NK cell functional profile in PBMC from 12 3DL1+B*27 and 14 3DL1+Bw6 subjects. Of 
the seven possible NK cell functional profiles, only the percent contribution of tri-functional 
NK cells to the total K562 response was significantly higher in the 3DL1+B*27 group versus 
3DL1+Bw6 SPs (2.99% [0.00%, 6.43%]) and (0.52% [0.00%, 7.36%]) for 3DL1+B*27 and 
3DL1+Bw6, respectively, p=0.019; Mann-Whitney U test). Based on these results we 
concentrated on the tri-functional NK subset in subsequent analyses. 
We next compared the K562 stimulated NK cells from 3DL1+B*27 individuals to that from 
carriers of 3DL1+Bw4. NK cells from *h/*y+B*57 carriers have previously been shown to 
have superior tri-functional potential compared to 3DL1+Bw6 and *h/*y+Bw4 subjects 
(Boulet et al. 2010; Kamya et al. 2011). Since HLA-B*57 is a Bw4 allele we excluded carriers of 
either HLA-B*57 or HLA-B*27 alleles from the 3DL1+Bw4 group. Although the tri-functional 
potential of NK cells from 13 3DL1+Bw4 subjects was lower (1.78% [0.00%, 5.71%]) than that 
from 3DL1+B*27 individuals the difference did not achieve statistical significance (p=0.2644; 
Mann-Whitney U test) (Figure 2A).  
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Fig. 1. NK cells from individuals carrying the 3DL1+HLA B*27 NK receptor-ligand pair 
have an increased functional potential. The frequency of NK cells that secrete IFN-γ (left), 
express CD107a (middle) or secrete TNF-α (right) in 3DL1 hmz individuals who carry HLA-
B*27 or HLA-Bw6. Each data point represents a separate individual. The bar through each 
scatter plot indicates the median frequency for the group. A Mann-Whitney U test was used 
to assess the significance of between-group comparisons (A). The percent contribution of 
seven different functional profiles to the total NK cell response to K562 HLA-devoid cells 
from individuals carrying 3DL1+B*27 (n=12) and 3DL1+Bw6 (n=14). Below the x-axis, dots 
refer to the presence of each functional marker (CD107a, IFN-γ and TNF-α) in that profile. 
The height of each bar represents the median for the group and the height of the error bar 
the interquartile range for that group. An asterisk (*) over the line linking two bars indicates 
that the contribution of that functional subset of the NK cell response was significantly 
different in the two study populations. A Mann-Whitney U test was used to assess the 
significance of between-group comparisons and p<0.05 was considered significant (B). 
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Fig. 2. Comparisons of the tri-functional potential of NK cells from study subjects with 
defined KIR/HLA combinations. Scatter plots show percent contribution of tri-functional NK 
cells to the total K562 stimulated response in individuals who are 3DL1+B*27, 3DL1+Bw4 
and 3DL1+Bw6 carriers (A), and *h/*y+B*27 and *l/*x+B*27 carriers (B). Each data point 
represents results from a separate individual. The data point represented by an empty 
square and triangle refer to individuals that carry both B*27 and B*57. The bar through each 
scatter plot indicates the median frequency for the group. A Mann-Whitney U test was used 
to assess the significance of between-group differences.  
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3DL1 hmz genotypes can be classified as either *h/*y or *l/*x depending on the 3DL1 alleles 
expressed. Previous work showed that NK cells from *h/*y+B*57 subjects had a significantly 
higher tri-functional potential than those from *l/*x+B*57 subjects. We therefore questioned 
whether NK cells from the 7 *h/*y+B*27 and 5 *l/*x+B27 individuals differed from each other 
in their tri-functional potential. The median (range) NK tri-functional potential was 2.56% 
(0.00%, 6.18%) and 3.57% (0.47%, 6.43%) for NK cells from carriers of the *h/*y+B*27 and 
*l/*x+B*27 genotypes, respectively (p=0.53; Mann-Whitney test), a difference that was not 
statistically significant (Figure 2B). Therefore, HLA-B*27 appears to be able to interact with 
NK receptor alleles in either the 3DL1 *h/*y and *l/*x genotype categories to educate NK 
cells for equivalent NK functional potential.  
3.3 NK cells from 3DL1+B*27 and *h/*y+B*57 carriers have a similar tri-functional 
potential 
Next we questioned whether the level of tri-functional potential of NK cells from 3DL1+B*27 
carriers was of a similar magnitude to that seen in NK cells from *h/*y+B*57 carriers. For this 
analysis we excluded the 2 3DL1+B*27 individuals who also expressed a B*57 allele and 
compared NK tri-functional potential in this group to that in 12 *h/*y+B*57 carriers. As seen 
in Figure 3A, although the tri-functional potential of NK cells from *h/*y+B*57 carriers was 
higher than that from 3DL1+B*27 carriers this difference did not achieve statistical 
significance (p=0.09; Mann-Whitney test). 
Pair-wise comparisons of the tri-functional potential of NK cells from carriers of 
*h/*y+B*57, 3DL1+B*27 and 3DL1+Bw4 revealed that only the comparison of *h/*y+B*57 
and 3DL1+Bw4 was statistically significant. NK cells from each of these groups had higher 
tri-functional potential than those from the 3DL1+Bw6 group (not shown). Small group 
sizes and large variability within groups likely contributed to the lack of statistical 
significance in the tri-functional potential between the *h/*y+B*57 and 3DL1+B*27 and the 
3DL1+B*27 and 3DL1+Bw4 groups. We performed another analysis testing for the 
significance of a trend towards declining NK functional potential among subjects with 
these 3DL1/HLA-B genotypes. The rationale for this came from epidemiological studies 
showing that the effect of B*57 on time to AIDS and VL control was greater in the 
presence of *h/*y than *l/*x 3DL1 genotypes and greater than that of B*27 on these 
outcomes in the presence of either 3DL1 genotype (Martin et al. 2007). When the tri-
functional potential of NK cells from these 3 3DL1/HLA-B genotypes were assessed. Using 
a test of trend we observed that this measure decreased as follows: *h/*y+B*57 > 
3DL1+B*27 > 3DL1+Bw4 (r=-0.40, p=0.01; Spearman’s correlation test). Together these 
results suggest that there is a hierarchy in the impact on NK cell education of HLA-B 
variants where B*57 is the most potent in the context of *h/*y genotypes followed by B*27 
in the context of 3DL1 genotypes. Furthermore the impact of these alleles is superior to 
that of other Bw4 alleles co-expressed with 3DL1 genotypes.  
4. Discussion 
We have presented results showing that NK cells from carriers of the 3DL1+B*27 KIR/HLA 
genotype combination have tri-functional responses to missing self that are 1) significantly 
higher than those from 3DL1+Bw6 and 2) have a tri-functional potential that falls between 
that of carriers of *h/*y+B*57 and 3DL1+Bw4. 
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Fig. 3. Comparisons of the tri-functional potential of NK cells from individuals carrying 
3DL1+B*27, *h/*y+HLA-B*57 and 3DL1+Bw4. Scatter plots show percent contribution of tri-
functional NK cells to the total K562 stimulated response in individuals who are 3DL1+B*27 
and *h/*y+B*57 carriers (A) or *h/*y+B*57, 3DL1+B*27 and 3DL1+Bw4 carriers (B). Each data 
point represents results from a separate individual. The bar through each scatter plot 
indicates the median frequency for the group. A Mann-Whitney U test was used to assess 
the significance of between-group differences (A). A Spearman’s correlation test was used to 
assess the significance of a trend towards decreasing functional potential in carriers of these 
genotype combinations (B).  
We previously showed that B*57 is superior to most other Bw4 alleles in educating NK 
cells through its interaction with 3DL1 NK receptors for functional potential as measured 
by responses to missing self on K562 cells (Boulet et al 2010; Kamya et al. 2011). These 
results suggested that B*57, an allele associated with slow time to AIDS and VL control, 
may contribute to viral control not only through its interaction with HIV epitopes 
recognized by CD8+ T cell but also through its interaction with 3DL1 inhibitory receptors 
on NK cells. B*27 is another allele associated with slow time to AIDS and VL control. We 
therefore sought to determine whether B*27 was also able to educate NK cells for potent 
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responses to missing self. The rationale for investigating the role of B*27 in educating NK 
cells for NK functional potential in HIV infected SP is that this allele is over represented 
among SP compared to the uninfected or HIV susceptible subjects. Among 101 SPs 
enrolled in the Canadian Cohort of HIV Infected SP typed to date 18 (17.8%) were B*27 
positive whereas in HIV susceptible subject enrolled in a Primary HIV Infection cohort 26 
of 434 (6%) expressed this allele (p<0.001; Fisher’s Exact test), an allele frequency similar 
to that seen in uninfected Caucasian (www.allelefrequencies.net). The frequency of 
individuals expressing both a B*27 allele and a homozygous 3DL1 genotype would be 
expected to be even lower. This provided the rationale for investigating this phenomenon 
in SPs in whom the frequency of the KIR/HLA genotype under investigation was higher 
than in uninfected subjects. We also reasoned that SPs with either controlled viremia or 
long term non progression would constitute a population with limited NK dysfunction 
due to HIV infection.  
Others have reported that HIV infection dysregulates NK cell subset distribution such that 
there is a reduction in the frequency of the CD56+CD16+ NK subset with cytolytic activity 
with an associated increase the frequency of an anergic CD56-/CD16+ subset (Mavilio et al. 
2005; Tarazona et al. 2002). VL seems to play a key role in this redistribution of NK cell 
subsets. Even though a decrease of cytotoxic NK cells is observed in SPs compared to 
healthy controls it is not as pronounced as that observed in viremic HIV infected progressor 
subjects (O'Connor et al. 2007; Barker et al. 2007). NK function may be altered by direct 
contact with HIV. The gp120 Envelope glycoprotein has been shown to suppress the 
activity, proliferation and survival of NK cells (Kottilil et al. 2006). Perturbations in the NK 
cell receptor repertoire have been reported in HIV infection, affecting both inhibitory and 
activating receptors (Kottilil et al. 2004; Mavilio et al. 2003; De Maria et al. 2003; O'Connor et 
al. 2007). Furthermore, HIV can escape NK cell recognition by restricting upregulation of 
activating NK cell receptor ligands such as NKp44L (Fausther-Bovendo et al. 2009), MICA 
and ULBP1 and 2 (Cerboni et al. 2007) and by preventing downregulation of HLA-C/E 
(Bonaparte and Barker 2004). Results reported by Kamya et al. demonstrated a negative 
correlation between NK cell tri-functional potential and VL suggesting VL and HIV 
infection negatively impact NK function (Kamya et al. 2011). In summary, although NK 
function in SPs may be affected by HIV infection the effect would be expected to be limited 
in this population. Our results demonstrate that NK cells from 3DL1+B*27 SPs can produce 
IFN-γ and TNF-α and express CD107a following K562 stimulation to a greater extent than 
those from 3DL1+Bw6. This finding is unlikely to be due to difference of VL as these 2 
groups had a similar VL (Table 2).  
We have previously shown that NK cells from SP who carry *h/*y+B*57 have a level of tri-
functional potential that is significantly higher than those from individuals carrying either 
3DL1*h/*y or 3DL1*l/*x genotypes with Bw4 alleles other than B*27 or B*57. The elevated 
tri-functional potential of NK cells from *h/*y+B*57 carriers depends on the presence of 
both the 3DL1*h/*y receptor genotype and HLA-B*57 since carriers of 3DL1*l/*x with HLA-
B*57 also have significantly lower NK tri-functional potential (Kamya et al. 2011). In 
contrast, we observed no differences in tri-functional potential in NK cells from HLA-B*27 
positive SPs carrying either the 3DL1*h/*y or *l/*x receptor genotypes. It should be noted 
that a limitation in making this assertion is the small number of subject who were 
*h/*y+B*27 versus *l/*x+B*27 available to make this comparison. Epidemiological studies 
found that compared to Bw6 hmz the B*57 effect on time to AIDS and VL control was 
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enhanced in the presence of 3DL1*h/*y compared to 3DL1*l/*x. Overall, the effect of B*27 on 
these outcomes was more moderate than that of B*57 in the presence of 3DL1 *h/*y. 
Compared to Bw6 hmz the B*27-80T allele B*2705 was more protective in the presence of 
3DL1*l/*x than in the presence of 3DL1*h/*y (Martin et al. 2007). All but one of the 
3DL1+B*27 group of subjects in our study population expressed B*27-80T alleles 
(Carrington, Martin, and van Bergen 2008). Furthermore, there is also evidence that B*2705 
has a greater affinity for one or more of the KIR3DL1*l allotypes (Luque et al. 1996). Our 
findings that NK cells from *h/*y+B*27 and *l/*x+B*27 carriers have similar levels of tri-
functional potential that may be more modest than of *h/*y+B*57 carriers is in line with B*27 
being able to interact with receptors encoded by 3DL1*h/*y and *l/*x genotypes in 
3DL1+B*27 carriers and this more effectively that B*57 interacting with receptors encoded 
by 3DL1*l/*x genotypes (Kamya et al. 2011). There is also a trend towards NK cells from 
3DL1+B*27 carriers having higher function that those from 3DL1+Bw4 individuals. These 
results argue in favour of HLA-B*27 and B*57 being unique among HLA-Bw4 antigens in 
their impact on educating NK cells for subsequent activity, although the effect of B*27 is 
more modest than that of B*57.  
According to the rheostat model of NK education, the strength of the inhibitory input 
received by NK cells determines the threshold of activation that is set in each NK cell. The 
higher the inhibitory input, the more likely the NK cell will pass the threshold required to 
respond to stimuli with an increased frequency of effector cells and an increased number of 
effector functions (Brodin, Karre, and Hoglund 2009). During development, NK cells must 
acquire sufficient inhibitory signals to prevent autoreactivity through recognition of ligands 
for inhibitory NK receptors (Valiante et al. 1997; Hoglund et al. 1997). The larger the 
contribution of given receptor-ligand pairing to NK cell inhibition under homeostatic 
conditions the more potent a missing self response will be when the ligand is lost. This 
situation would be encountered in a setting of HIV infection where HIV encoded Nef 
downmodulates HLA-A and B molecules from the cells surface abrogating inhibitory 
signals mediated by 3DL1 receptors (Collins et al. 1998; Cohen et al. 1999). 
In this report we have focused on comparisons of the tri-functional subset of NK cells. This 
was done because the percent contribution of this subset to the entire K562 stimulated 
response was the only functional subset that differed between carriers 3DL1+B*27 and a 
KIR/HLA receptor-ligand combination unable to signal through 3DL1 NK receptors. NK 
cells able elicit 3 functions are more potent in terms of the intensity of each of their functions 
than corresponding mono-functional NK cells (Kamya et al. 2011). This is similar to what 
has been reported for poly- versus mono-functional CD8+ T cells (Darrah et al. 2007; Betts et 
al. 2006) Poly-functional HIV-specific CD8+ T cells in SPs may play a role in superior anti-
HIV activity (Betts et al. 2006; Makedonas and Betts 2011). This is still a controversial area as 
the low VL seen in SPs may preserve multi-functional HIV-specific immune response. 
Although the biological relevance of poly-functional antigen specific CD8+ T cells in HIV 
infection is not yet clear, they do serve as an indicator of an effective response to HIV. Our 
experiments did not directly test the anti-viral activity of NK cells since we did not use HIV 
infected cells as stimuli. The role of tri-functional NK cells in inhibition of viral replication 
warrants further investigation.  
If stimulation with HIV infected cells produces higher functionality in NK cells from 
3DL1+B*27 versus 3DL1+Bw6 carriers and tri-functional NK cells are endowed with a 
superior capacity to suppress viral replication it would be interesting to study the ability 
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of NK cells from 3DL1+Bw6 for other NK cells functions. Our results demonstrate that 
these individuals have a limited NK cell tri-functional potential upon missing self 
stimulation. Since these SPs are able to control viral replication and/or maintain CD4 
counts above 400 for 7 or more years it is not unreasonable to assume that NK cells from 
these subjects possess other NK function. NK cells are known to mediated antibody-
dependent cell-mediated cytotoxicity which has been shown to play a role in controlling 
viral replication (Forthal, Landucci, and Daar 2001) and may play a role in preventing 
infection (Rerks-Ngarm et al. 2009). In addition, NK cells are also able to regulate antiviral 
immunity by modulating DC function (Gerosa et al. 2002; O'Leary et al. 2006). In the 
presence of HIV replication the cross talk between NK cells and DC is impaired (Mavilio 
et al. 2006; Melki et al. 2010; Alter et al. 2010). It would be interesting to assess whether 
the interaction between NK cells and DC is maintained in SPs, particularly in 3DL1+Bw6 
carriers. 
5. Conclusion 
We have demonstrated that NK cells from 3DL1+B*27 SPs have a higher tri-functional 
potential following K562 stimulation than those from 3DL1+Bw6. A test of trend found that 
NK tri-functional potential declines significantly in NK isolated from carriers of the 
following genotypes: *h/*y+B*57 > 3DL1+B*27 > 3DL1+Bw4. Our results suggest that 
although the protective effect on HIV infection conferred by HLA-B*27 is mediated in part 
by CD8+ T cells recognizing HIV epitopes restricted by this allele, the protective effect of 
this alleles may also be mediated by its interaction with inhibitory 3DL1 receptors. HLA-
B*27, like HLA-B*57, appears to have an impact on NK education that is superior to that of 
other Bw4 alleles. Although this remains to be demonstrated experimentally we 
hypothesize that in carriers of certain 3DL1 and HLA-B*27 or HLA-B*57 genotypes, virus-
infected cells that have down modulated the HLA ligand for their inhibitory 3DL1 NK 
receptors may be able to recruit a larger number NK cells with multiple functions, which 
can play a role in viral control. Such information is relevant to vaccine design by providing 
a rationale for modulating NK activity at the time of vaccination to favor developing 
protective immunity. 
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